Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 21, 2025
PDL Changes Effective Date: January 1, 2026

The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2026, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	**RECOMMENDED for PREFERRED STATUS**
Sickle Cell Agents	**Casgevy** (exagamglogene autotemcel)
Sickle Cell Agents	**Lyfgenia** (lovotibeglogene autotemcel)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	**RECOMMENDED for NON-PREFERRED STATUS**
Antivirals, Topical	**Zelsuvmi** (berdazimer)
Bone Resorption Suppression and Related Agents	**Bomyntra** (denosumab-bnht)
Cytokine & CAM Antagonist	**Anzupgo** (delgocitinib)
Hereditary Angioedema Treatments	**Dawnzera** (donidalorsen)
Hereditary Angioedema Treatments	**Ekterly** (sebetralstat)
Hypoglycemics, Insulins & Related Agents	**Kirsty** (insulin aspart-xjhz)
Hypoglycemics, Insulins & Related Agents	**Merilog** (insulin aspart-szjj)
Miscellaneous Brand/Generic, Miscellaneous	**Brinsupri** (brensocatib)
Miscellaneous Brand/Generic, Miscellaneous	**Harliku** (nitisinone)
Muscular Dystrophy Agents	**Jaythari** (deflazacort)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 21, 2025
PDL Changes Effective Date: January 1, 2026

MISSISSIPPI DIVISION OF MEDICAID

An Asterisk (*) denotes a new class added to the Preferred Drug List (PDL).

PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
Acne Agents – Anti-Infectives	erythromycin gel, solution	X	
Acne Agents – Others/Combination Products	clindamycin/benzoyl peroxide 1%-5% gel (without pump)	X	
Angiotensin Modulators – ARB Combinations	sacubitril/valsartan; olmesartan/amlodipine/HCTZ	X	
Angiotensin Modulators – ARB Combinations	Entresto; amlodipine/valsartan/HCTZ		X
Antibiotics (GI) & Related Agents	vancomycin capsule	X	
Antibiotics (Miscellaneous) – Macrolides	E.E.S 200 Suspension		X
Antibiotics (Miscellaneous) – Oxazolidinones	linezolid tablet	X	
Anticoagulants – Oral	dabigatran	X	
Anticoagulants – Oral	Pradaxa; Xarelto dose pack		X
Antidepressants, Other	venlafaxine HCl ER tablet	X	
Antidepressants, SSRIs	fluoxetine solution	X	
Antifungals (Topical) – Antifungals	tavaborole	X	
Antifungals (Topical) – Antifungals	miconazole-zinc oxide-petrolatum ointment; Micotrin AP		X
Antifungals (Vaginal)	3-Day Vaginal Cream	X	
Antifungals (Vaginal)	miconazole 3 kit		X
Antimigraine Agents, Acute Treatment – Injectables	sumatriptan cartridge		X
Antimigraine Agents, Acute Treatment – Nasal	zolmitriptan spray	X	

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 21, 2025
PDL Changes Effective Date: January 1, 2026

MISSISSIPPI DIVISION OF MEDICAID

PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
Antiparasitics (Topical) – Pediculicides	spinosad	X	
Antiparasitics (Topical) – Pediculicides	Natroba		X
Antiparkinson's Agents (Oral) – Others	carbidopa; bromocriptine capsule		X
Antipsychotics – Oral	lurasidone	X	
Antipsychotics – Oral	Vraylar		X
Antiretrovirals – Capsid Inhibitors	Yeztugo	X	
Antiretrovirals – Protease Inhibitors (Non-Peptidic)	darunavir 600mg & 800mg tablet	X	
Antiretrovirals – Protease Inhibitors (Non-Peptidic)	Prezista 600mg & 800mg tablet		X
Antivirals (Oral) – COVID-19	Paxlovid	X	
Antivirals (Topical)	acyclovir cream, ointment	X	
Antivirals (Topical)	Zovirax cream		X
Atopic Dermatitis	Ebglyss	X	
Beta Blockers, Antianginals & Sinus Node – Antianginals	ranolazine ER	X	
Bone Resorption Suppression And Related Agents – Others	Bildyos; Bilprevda	X	
Bronchodiltors & COPD Agents – Anticholinergic-Beta Agonist – Glucocorticoids Combinations	Breztri Aerosphere; Trelegy Ellipta	X	
Bronchodilators & COPD Agents – Anticholinergics & COPD Agents	Spiriva Respimat	X	
Bronchodilators & COPD Agents – Anticholinergics & COPD Agents	Incruse Ellipta		X

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 21, 2025
PDL Changes Effective Date: January 1, 2026

MISSISSIPPI DIVISION OF MEDICAID

PDL STATUS CHANGES			
THERAPEUTIC CLASS	DRUG	New Recommended Status	
		PREFERRED	NON-PREFERRED
Calcium Channel Blockers – Long-Acting	Tiadylt ER	X	
Cephalosporins & Related Agents (Oral) – Cephalosporins First Generation	cefadroxil tablet		X
Colony Stimulating Factors	Releuko	X	
Cytokine & CAM Antagonists	adalimumab-aaty autoinject; Cyltezo; Hadlima; Imuldosa; Pyzchiva; Selarsdi; Yuflyma	X	
Factor Deficiency Products – Factor IX	Rebinyn	X	
Glucocorticoids (Inhaled) – ICS/LABA Combinations	fluticasone-salmeterol HFA		X
Idiopathic Pulmonary Fibrosis	pirfenidone	X	
Intranasal Rhinitis Agents – Corticosteroids	Nasonex 24 Hour Allergy Spray	X	
NSAIDs – COX II Selective	meloxicam capsule		X
NSAIDs – Non-Selective	indomethacin ER	X	
NSAIDs – Non-Selective	ketoprofen capsule		X
Ophthalmic Agents – Dry Eye Agents	Eysuvis	X	
Pancreatic Enzymes	Pertzye	X	
Platelet Aggregation Inhibitors	ticagrelor	X	
Platelet Aggregation Inhibitors	Brilinta		X
Prenatal Vitamins	Folivane-OB; Select-OB + DHA; Taron-C DHA; Vit 3; Vitafol FE Plus; Vitafol-OB; Vitafol-One; Vitafol Ultra; Wescap-C DHA	X	

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 21, 2025
PDL Changes Effective Date: January 1, 2026

PDL STATUS CHANGES			
THERAPEUTIC CLASS	**DRUG**	**New Recommended Status**	
		PREFERRED	**NON-PREFERRED**
Select Contraceptive Products – Intravaginal	Annovera		X
Select Contraceptive Products – Transdermal Contraceptives	Twirla; Zafemy	X	